Expression of p53, KI-67 and c-erb B2 in growth hormone- and/or prolactin-secreting pituitary adenomas

Arquivos de Neuro-Psiquiatria

Volumn 64, Issue 1, 2006, Pages 60-66

  Botelho, Carlos Henrique A ^a,e   De Magalhães, Albino Verçosa ^b   De Mello, Paulo Andrade ^c   Schmitt, Fernando C ^d   Casulari, Luiz Augusto ^c  

^a Centro Universitário Projeção   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^d University of Porto   (Portugal)

^e SQSW 105 ^*  (Brazil)

Author keywords

c erb B2; Growth hormone; Immunohistochemistry; Ki 67; p53; Pituitary adenomas; Prolactin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH HORMONE; KI 67 ANTIGEN; PROLACTIN; PROTEIN P53;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH HORMONE RELEASE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; PROLACTIN RELEASE; PROTEIN EXPRESSION;

EID: 33646448886     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2006000100013     Document Type: Article

References (28)

1. Herman-Bonert VS, Prager D, Melmed S. Growth hormone. In Melmed S (ed). The pituitary. Cambridge: Blackwell Science, 1995:98-135.
2. Zurschmiede C, Ladolt AM. Distribution of growth hormone and prolactin in secretory granules of the normal and neoplastic human adenohypophysis. Virchows Arch B 1987;53:308-315.
3. Mulchahey JJ, Jaffe RB. Detection of a potential progenitor cell in the human fetal pituitary that secretes both growth hormone and prolactin. J Clin Endocrinol Metab 1988;66:24-32.
4. Davis JRE. Tissue-specific regulation of prolactin gene expression. J Endocrinol 1990;125:171-173.
5. Kovacs K, Horvath E. Pathology of growth hormone-producing tumors of the human pituitary. Semin Diag Path 1986;3:18-33.
6. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990;71:1427-1433.
7. Faglia G, A rosio M, Spada A. GS protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. Metabolism 1996;45:117-119.
8. Melmed S, Shimon I. Genetical basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997;82:1675-1681.
9. Levy A, Hall L, Yeudall WA, Lightman SL. P53 gene mutations in pituitary adenomas: a rare events. Clin Endocrinol (Oxf) 1994;41:809-814.
10. Oliveira MC, Marroni CP, Pizarro CB, Lima JFP, Coutinho LMB. Expression of p53 protein in pituitary adenomas. Braz J Med Biol Res 2002;35:561-565.
11. Suliman M, Royds J, Cullen D, et al. Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol 2001;54:317-325.
12. Suhardja A, Kovacs K, Rutka J. Genetic basis of pituitary adenomas invasiveness: a review. J Neurooncol 2001;52:195-204.
13. Yin D, Tamaki N, Kokunai T, Yasuo K, Yonezawa K. Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression. J Clin Neurosci 1999;6:326-331.
14. Asano K, Tajika Y, Huang MC, Takakura K. The relation between cell-proliferation activity and secretion in pituitary adenoma: a review of 63 cases. No To Shinkei 1996;48:534-539.
15. Daita G, Yonemasu Y. Dural invasion and proliferative potential of pituitary adenomas. Neurol Med Chir 1996;36:211-214.
16. Atkin SL, Green VL, Hipin LJ, Landolt AM, Foy PM, Jeffreys RV, White MC. A comparison of proliferation indices in human anterior pituitary adenomas using formalin-fixed and in vitro cell culture. J Neurosurg 1997;87:85-88.
17. Mastronardi L, Guiducci A, Puzzilli F, Maira G. Anterior pituitary adenomas in patients aged more than 65 years: analysis of growth fraction (using the MIB-1 monoclonal antibody) and of clinical features in comparison to younger patients. Clin Neurol Neurosurg 2002;104:44-48.
18. Kumar V, Abbas AK, Fausto N. In Robbins & Cotran (eds). Pathologic basis of disease. 7.ed. Philadelphia: Elsevier Saunders, 2005.
19. Penar PL, Nathan DJ, Nathan MH, Salsali A. Pituitary tumor diagnosis and treatment. Curr Neurol Neurosci Rep 2002;2:236-245.
20. Alves VAF, Bacchi CE, Vassallo J. Manual de Imuno-histoquímica. Sociedade Brasileira de Patologia, 1999:35-37.
21. Landis CA, Harsh G, Lyons J, Davis FM, Bourne HR. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J Clin Endocrinol Metab 1990;71:1416-1420.
22. Casulari LA, Celotti F, Naves LA, Domingues L, Papadia C. Case report: persistence of hyperprolactinemia after treatment of primary hypothyroidism and withdrawal of the long term use of estrogen. Are the tuberoinfundibular dopaminergic neurons permanently lesioned? Arq Bras Endocrinol Metab 2005, in press.
23. Onguru O, Scheithauer BW, Kovacs K, et al. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol 2004;17:772-780.
24. Kong Y, Ren Z, Su C, Wang R. Detection of serum epidermal growth factor receptor in the diagnosis of proliferation of pituitary adenoma. Zhonhua Yi Xue Za Zhi 2002;82:527-529.
25. Schreiber S, Seager W, Ludecke DK. Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1999;1:213-220.
26. Blevins LS Jr, Verity DK, Allen G. Aggressive pituitary tumors. Oncology 1998;12:1307-1312.
27. Nakabayashi H, Sunada I, Hara M. Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 2001;49:1193-1194.
28. Mastronardi L, Guiducci A, Puzzilli F. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 2001;1:12.